✦ LIBER ✦

Oncolytic Virus Therapy Using Genetically Engineered Herpes Simplex Viruses

✍ Scribed by Tomoki Todo

Book ID: 111390314
Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 905 KB
Volume: 15
Category: Article
ISSN: 0914-7470
DOI: 10.1111/j.1749-0774.2002.tb00109.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis of genetically engineered oncol

Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures

✍ Passer, B J; Wu, C-l; Wu, S; Rabkin, S D; Martuza, R L 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 673 KB

Expression of human immunodeficiency vir

Expression of human immunodeficiency virus type 1gaggene using genetically engineered herpes simplex virus type 1 recombinants

✍ Angela Rösen-Wolff; Karl Raab; Lothar Zöller; Gholamreza Darai; Josef Eberle; Fr 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 638 KB

Use of Positron Emission Tomography to T

Use of Positron Emission Tomography to Target Prostate Cancer Gene Therapy by Oncolytic Herpes Simplex Virus

✍ Michael Mullerad; David P. Eisenberg; Timothy J. Akhurst; Prasad S. Adusumilli; 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 391 KB

Treatment of cholangiocarcinoma with onc

Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy

✍ Jarnagin, W R; Zager, J S; Hezel, M; Stanziale, S F; Adusumilli, P S; Gonen, M; 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 190 KB

Pilot Study of Oncolytic Viral Therapy U

Pilot Study of Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) Against Recurrent Metastatic Breast Cancer

✍ Hideto Kimata; Tsuneo Imai; Toyone Kikumori; Osamu Teshigahara; Tetsuro Nagasaka 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 205 KB

Development of a second-generation oncol

Development of a second-generation oncolytic Herpes simplex virus expressing TNFα for cancer therapy

✍ Z. Q. Han; M. Assenberg; B. L. Liu; Y. B. Wang; G. Simpson; S. Thomas; R. S. Cof 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

## Abstract ## Background Tumour necrosis factor alpha (TNFα) therapy is a promising anti‐cancer treatment when combined with radiotherapy due to its potent radio sensitising effects, but systemic toxicity has limited its clinical use. Previously, non‐replicative adenovirus vectors have been used